Brief: Esperion Receives Five Year Patent Extension for Bempedoic Acid, Contained in NEXLETOL and NEXLIZET
14/05/2024 13:44
May 14 (Reuters) - Esperion Therapeutics Inc ESPR.O :
* ESPERION RECEIVES FIVE YEAR PATENT EXTENSION FOR BEMPEDOIC
ACID,
CONTAINED IN NEXLETOL® AND NEXLIZET®
Source text for Eikon: ID:nGNX316ySx
Further company coverage: ESPR.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Esperion Therapeutics
See all newsNASDAQ TRADE HALT CONTINUES REASON NOT AVAILABLE AT 03:58 AM
NASDAQ TRADE HALT CONTINUES TRADING HALTED; FOR INFORMATION REQUESTED BY NASDAQ AT 03:28 AM
NASDAQ TRADE HALT CONTINUES TRADING HALTED; FOR INFORMATION REQUESTED BY NASDAQ AT 03:28 AM
NASDAQ TRADE HALT TRADING HALTED; FOR INFORMATION REQUESTED BY NASDAQ AT 07:50 PM
U.S. RESEARCH ROUNDUP- Applied Materials, Axsome Therapeutics, Onsemi